According to a new research report “Diabetic Foot Ulcer Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, diabetic foot ulcer therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

Diabetic Foot Ulcer Therapeutics Pipeline Insights

A diabetic foot ulcer is an open sore or wound that occurs in approximately 15% of patients with diabetes and is commonly located in the bottom of the foot. People with diabetes are at higher risk of developing neuropathy as increased blood glucose levels lead to nerve damage. Poor blood circulation, hyperglycemia, and deprived nutrition are some other risk factors associated with the onset of diabetic foot ulcer.

Symptoms of diabetic foot ulcer vary from person to person. Some of the commonly reported symptoms include numbness and tingling sensation, skin discoloration, blisters, and red streaks. The disease can be diagnosed by physical examination and imaging techniques including magnetic resonance imaging (MRI), radiography, and bone scan. Treatment of the disease includes surgical procedures such as shaving or excision of bone and the correction of various deformities to remove pressure from the affected area. Moreover, dead skin and tissue removal, blood glucose management, medication, and regular dressings are also help to manage diabetic foot ulcer.

REGRANEX (Janssen Pharmaceuticals Inc.), a topically administered gel, is one of the marketed products indicated for the treatment of diabetic foot ulcer.

Insights into Pipeline Segments

According to the research, most of the therapeutic drug candidates are being developed for topical administration. It has been found that topical route of administration is easy to use, non-invasive, and effective method of treatment, and also ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive the Diabetic Foot Ulcer Pipeline

Companies involved in the development of diabetic foot ulcer therapeutics have shown positive clinical results in various phases of drug development. For instance, FirstString Research Inc. is developing topically administered Granexin gel, currently in phase III stage of development. Granexin gel demonstrated positive proof-of-concept efficacy and benign safety in three placebo-controlled, randomized, and double-blinded clinical trial studies. Another company, Charsire Biotechnology Corp., is evaluating the safety and efficacy of its drug candidate, CSTC1, in patients suffering from diabetic foot ulcer.

Browse Detailed Report at:https://www.pharmaproff.com/report/diabetic-foot-ulcers-therapeutics-pipeline-analysis

Strategic Advancements Play a Pivotal Role in the Diabetic Foot Ulcer Therapeutics Development

In November 2018, Destiny Pharma plc and University of Southampton entered into a research collaboration to examine the use of Destiny Pharma plc’s novel XF compounds to prevent, control, and eradicate chronic clinical infections, including diabetic foot ulcer and cystic fibrosis. Similarly, in February 2016, Gemstone Biotherapeutics LLC licensed new wound-healing technology from Johns Hopkins University for the treatment of diabetic foot ulcer.

Janssen Pharmaceuticals Inc., Destiny Pharma plc, ASKLEP Inc., FirstString Research Inc., RHEACELL GmbH & Co. KG, GlaxoSmithKline plc, Remedor Biomed Ltd., Janssen Pharmaceuticals Inc., and Biotec Pharmacon ASA are some of the key companies involved in the development of diabetic foot ulcer therapeutics.

Diabetic Foot Ulcer Therapeutics Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of diabetic foot ulcer. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the diabetic foot ulcer therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to diabetic foot ulcer.